Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 10/20 | 0.82 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.82 |
| ▸ | PGR | P06401 | 4/20 | 0.82 |
| ▸ | USP2 | O75604 | 4/20 | 0.82 |
| ▸ | LMNA | P02545 | 2/20 | 0.82 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.82 |
| ▸ | MAPT | P10636 | 2/20 | 0.82 |
| ▸ | MLNR | O43193 | 1/20 | 0.82 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.82 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.82 |
| ▸ | PPARG | P37231 | 1/20 | 0.82 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.82 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.82 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.82 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.82 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.81 |
| ▸ | DRD2 | P14416 | 1/20 | 0.81 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.81 |
| ▸ | MEN1 | O00255 | 1/20 | 0.72 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4210412 | 1.00 | NR3C1 (0.82) | NR3C1CYP3A4PGRUSP2LMNA | |
| SCHEMBL11229005 | 0.94 | NR3C1 (0.78) | NR3C1CYP3A4PGRUSP2LMNA | |
| SCHEMBL11842222 | 0.92 | NR3C1 (0.83) | NR3C1CYP3A4PGRUSP2LMNA | |
| SCHEMBL10873405 | 0.92 | NR3C1 (0.83) | NR3C1CYP3A4PGRUSP2LMNA | |
| SCHEMBL11845108 | 0.92 | NR3C1 (0.83) | NR3C1CYP3A4PGRUSP2LMNA | |
| SCHEMBL11842212 | 0.92 | NR3C1 (0.83) | NR3C1CYP3A4PGRUSP2LMNA | |
| SCHEMBL9835214 | 0.92 | NR3C1 (0.83) | NR3C1CYP3A4PGRUSP2LMNA | |
| SCHEMBL8988215 | 0.92 | NR3C1 (0.85) | NR3C1CYP3A4PGRUSP2LMNA | |
| SCHEMBL9653395 | 0.92 | NR3C1 (0.85) | NR3C1CYP3A4PGRUSP2LMNA | |
| SCHEMBL8988209 | 0.92 | NR3C1 (0.85) | NR3C1CYP3A4PGRUSP2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8785425-B2 | 11β-hydroxyandrosta-4-ene-3-ones | SUN PHARMA ADVANCED RESEARCH COMPANY LTD. | 2014-07-22 | — | — | US | disclosed |
| EP-2004667-B1 | NOVEL 11 BETA - HYDROXYANDROSTA-4-ENE-3-ONES | SUN PHARMA ADVANCED RES CO LTD (IN) | 2013-09-04 | — | — | EP | disclosed |
| US-20090054388-A1 | NOVEL 11 BETA-HYDROXYANDROSTA-4-ENE-3-ONES | SUN PHARMA ADVANCE RESEARCH COMPANY (IN) | 2009-02-26 | — | — | US | disclosed |
| US-6197761-B1 | ANTIINFLAMMATORY, ANTALLERGEN AGENTS | GLAXO WELLCOME INC. | 2001-03-06 | — | — | US | disclosed |
| EP-0876392-B1 | LACTONE DERIVATIVES OF 17.BETA.-CARBOXY, CARBOTHIO AND AMIDE ANDROSTANE DERIVATIVES | GLAXO GROUP LTD (GB) | 2000-07-05 | — | — | EP | disclosed |
| EP-0876392-A1 | LACTONE DERIVATIVES OF 17.BETA.-CARBOXY, CARBOTHIO AND AMIDE ANDROSTANE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 1998-11-11 | — | — | EP | disclosed |
| WO-1997024365-A1 | LACTONE DERIVATIVES OF 17.BETA.-CARBOXY, CARBOTHIO AND AMIDE ANDROSTANE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 1997-07-10 | — | — | WO | disclosed |
| US-4650610-A | Androstane carbothioic acids | GLAXO GROUP LIMITED (GB) | 1987-03-17 | — | — | US | disclosed |
| US-4578221-A | Androstane carbothioic acids | GLAXO GROUP LIMITED (GB) | 1986-03-25 | — | — | US | disclosed |
| US-4335121-A | TOPICAL ANTIINFLAMMATORY AGENTS | GLAXO GROUP LIMITED (GB) | 1982-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054388-A1 | NOVEL 11 BETA-HYDROXYANDROSTA-4-ENE-3-ONES | HSD11B1, HSD3B1, HSD3B2 | NR3C1 37/4885CYP3A4 127/4885PGR 146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.